Shanghai Ninth People's Hospital Licenses Chronic Wound Phototherapy Gel Patent for RMB 610,000 to Shanghai Zhongyi Daily Chemical Co., Ltd.

Recently, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine released a public notice on the transformation of scientific and technological achievements. The hospital intends to transfer its intellectual property through listed trading via the Shanghai Technology Exchange."Fibrin Glue and Its Medical Devices and Their Application in Adjuvant Phototherapy"Patent technology has been successfully transferred to Shanghai Zhongyi Daily Chemical Co., Ltd., with the transfer amountRMB 610,000。

The inventors of the patented technology are Professor Yao Min’s team from Shanghai Jiao Tong University. This teamInnovatively Combining Fibrin Gel with Red and Blue Light Therapy, the newly developed therapeutic system demonstrates unique advantages in the treatment of hard-to-heal wounds, such as diabetic wounds and pressure injuries.

The assignee of this patented technology, Shanghai Zhongyi Daily Chemical Co., Ltd., is a wholly-owned subsidiary of Shanghai Charming Cosmetics Co., Ltd. Well-known brands under Shanghai Zhongyi Daily Chemical Co., Ltd. include Kans, One Leaf, and Red Elephant, covering daily chemical product sectors such as skincare, facial masks, and maternal and infant care.

Notably, Shanghai Zhongyi Daily Chemical Co., Ltd., a manufacturing and processing subsidiary of Chicony Holdings, possesses internationally leading production and warehousing equipment and management systems, and has been included in the list of enterprises proposed for recognition as High-Tech Enterprises in Shanghai.

This patented technology is particularlyFor Chronic Wounds with Significant Clinical Treatment Challenges, including diabetic foot ulcers, pressure injuries, venous ulcers, and burn wounds,Achieves Effective Integration of Dual Mechanisms for Anti-Infection and Wound Healing Promotion, Providing a Novel Therapeutic Strategy for Chronic Wound Management。

Chronic WoundsAs a favorable environment for the proliferation of pathogenic microorganisms, its treatment faces severe challenges.The toxic enzymes secreted by these microorganisms directly damage host tissues, disrupt the normal wound healing process, exacerbate inflammation, delay healing, and even lead to severe complications. Infected wounds require patients to make frequent hospital visits for treatment, imposing not only a substantial economic burden but also significant psychological stress.

According to statistics,The 5-Year Mortality Rate of Chronic Wounds Is Comparable to That of Cancer, its incidence and associated treatment costs (including severe consequences such as amputation and death) continue to rise, and it has been identified by the U.S. Food and Drug Administration as a top priority in the research field.

However, unlike diseases such as cancer, for which treatment strategies are well-established, the management of chronic wounds currently remains at"Trial and Error"stage. Due to its complex and diverse etiology, involving multiple factors such as infections by various pathogens, biofilm formation, and pro-inflammatory bacterial toxins, conventional treatment modalities are often both costly and limited in efficacy.

Over the past 26 years, there have been onlyBecaplerminThis drug has received FDA approval for the treatment of chronic wounds, butHowever, the drug carries a carcinogenic risk and requires a safety warning label.. Currently, commonly used clinical interventions include debridement, negative pressure wound therapy, topical application of growth factors, and coverage with skin substitutes; however, these traditional methods are generally associated with prominent issues such as prolonged treatment duration, suboptimal efficacy, and high costs.

Among novel therapeutic approaches,Safe, Non-Invasive Phototherapy Technologyhas attracted significant attention in recent years, primarily includingPhotodynamic Therapy and Photobiomodulation: Two Approaches. Among these, photodynamic therapy utilizes blue light to activate photosensitizers, generating an antibacterial effect that effectively eradicates a wide range of bacteria; whereas photobiomodulation employs red or near-infrared light irradiation to stimulate the activity of cytochrome c oxidase (mitochondrial respiratory chain complex IV), promoting the dissociation of nitric oxide from the enzyme complex, thereby improving mitochondrial function and accelerating wound healing.

Although these phototherapy methods have demonstrated significant efficacy in hospital settings, the devices currently used to deliver phototherapy are generally bulky, require operation by trained professionals, entail high treatment costs, are inconvenient to use, and cannot adapt to wounds of varying shapes. These limitations severely hinder the widespread adoption of phototherapy technology in home care scenarios.

Addressing the Dual Dilemma of Limited Efficacy in Traditional Therapies and Low Compatibility of Existing Phototherapy Devices, the patented technology involved in this transaction provides an innovative solution—Phototherapeutic Gel System Based on Fibrin Carriers Loaded with TQ/NADH.This technology involves mixing fibrinogen with thrombin to form a gel carrier, which is carefully loaded with blue light-sensitive thymoquinone (TQ) and red light-responsive reduced nicotinamide adenine dinucleotide (NADH). Calcium ions are specifically added to enhance the stability of the fibrin network and the mechanical properties of the gel. Its core lies inA Fibrin Gel Developed to Synergize with Phototherapy Technology。

Professor Yao Min’s team has demonstrated significant technological advancement and multiple advantages, with its core innovation lying inPioneering the Deep Integration of Biomaterials Technology with Phototherapy Medicine, and established a comprehensive multimodal treatment system.

This technology forms a biocompatible gel carrier by mixing fibrinogen (at concentrations ranging from 2 to 10 mg/mL) with thrombin (at levels of 1 to 10 U/mL) in equal volumes, and carefully incorporates two key active ingredients within it:Blue light-sensitive thymoquinone (TQ) and red light-responsive reduced nicotinamide adenine dinucleotide (NADH).

The Combination of These Two Active IngredientsAchieves the perfect integration of dual mechanisms: anti-infection and wound healing promotionUnder blue light irradiation, TQ can be specifically activated to exert antibacterial activity, effectively eliminating pathogenic microorganisms at the wound site; whereas under red light, NADH synergizes with the mitochondrial respiratory chain to significantly improve cellular energy metabolism and promote tissue repair. This technology is particularly targeted at chronic wounds that are clinically challenging to treat, including diabetic foot ulcers, pressure injuries, venous ulcers, and burn wounds. By effectively integrating with red and blue light LED therapeutic devices, it forms a complete medical device system, providing a novel therapeutic strategy for chronic wound management.

Notably, this technology addresses the issue of reactive oxygen species damaging healthy tissues in traditional photodynamic therapy (PDT) through sophisticated formulation design, while simultaneously achievingAnti-Infection and Wound Healing Promotionperfect balance. Experiments have confirmed that this combination therapy not only effectively induces macrophage polarization toward the anti-inflammatory M2 phenotype, but also significantly improves mitochondrial function under inflammatory stress through energy metabolism-immune regulation pathways.

Furthermore, the team utilized a meticulously designed fibrin gel carrier to precisely load the photosensitizer thymoquinone (TQ) and the mitochondrial function modulator NADH. Notably, NADH was incorporated into mesoporous silica nanoparticles (MSNs) to achieve controlled sustained release, thereby ensuring the stability and long-lasting efficacy of the components.

This innovative therapeutic strategy transforms phototherapy, traditionally requiring a professional medical setting, into a convenient home-based treatment regimen. By employing simple steps of gel application and light irradiation, it significantly shortens treatment time while achieving dual efficacy in infection control and accelerated wound healing. This approach provides an ideal solution for the home management of chronic wounds, such as diabetic foot ulcers and pressure injuries, demonstrating substantial clinical value and market potential.

Currently, the treatment of chronic wounds continues to face clinical challenges, including difficult healing, high recurrence rates, and significant impairment of patients’ quality of life, prompting global companies and research institutions to actively explore new therapeutic approaches.

Internationally, UK-based Smith & Nephew PLC and US-based Organogenesis Holdings are both developing phototherapy products based on fibrin gels. Smith & Nephew’s light-activated bio-gel dressing is in Phase I/II clinical trials; its core technology involves loading photosensitizers into a fibrinogen gel, which generates reactive oxygen species (ROS) upon activation by blue light to exert bactericidal effects. The target indication is infected chronic wounds, such as diabetic foot ulcers.

Organogenesis’ fibrin-based light-responsive gel focuses on red-light responsiveness, aiming to enhance the controllability of gel degradation and promote fibroblast proliferation upon red-light irradiation. This product, targeting venous ulcers and burn wounds, has entered Phase II clinical trials.

In addition, the bioactive gel phototherapy system developed by the U.S. company ConvaTec Group has also entered Phase II clinical trials. This system utilizes recombinant human fibrinogen-like components combined with low-energy blue light therapy to synergistically reduce biofilm formation, for the treatment of diabetic foot ulcers and pressure injuries.

In China, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical’s R&D pipeline focuses more on the phototherapy devices themselves. Its photodynamic therapy (PDT)-compatible device, designed for use with “Fumida” (hemoporfin), is in Phase I clinical trials. The device enhances the precision of PDT for conditions such as skin tumors and port-wine stains by optimizing 630 nm red light and 470 nm blue light sources.

The infrared non-invasive phototherapy device and its accompanying gel dressing, developed by Changzhi Guangyisheng Technology, are currently in the preclinical stage. This system utilizes infrared light (near-infrared spectrum) and features a patch designed to be compatible with fibrin gel, aiming to promote wound vascularization. It is indicated for chronic skin wounds and inflammatory dermatoses.

Overall, although various innovative solutions combining phototherapy with biomaterials have emerged in the field of chronic wound care, most technologies still face challenges such as prolonged clinical validation cycles, complex manufacturing processes, and high barriers to home-use adaptation. The successful translation of this patented technology provides companies with a new entry point for positioning themselves in this sector. However, to realize its true clinical value and market potential, rigorous clinical validation, optimization of manufacturing processes, and clear commercial positioning remain essential. Future market competition will depend on multiple factors, including the efficacy of the technical solution, cost control, and user experience.